Table 1.
Summary of IHC, ALK fusion status, and previous treatment of each patient case.
| IHC Staining |
ALK Evaluation |
Prior Therapy |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Case Number | Desmin | SMA | Estrogen Receptor | Progesterone Receptor | ALK IHC | ALK FISH | Fusion | No. of Prior treatments prior to ALK targeted therapy | Prior Chemo or TKI | Prior Endocrine therapy |
| 1 | Negative | Positive | Positive | Positive | Equivocal | Not performed | FN1-ALK | 1 | 0 | Exemestane |
| 2 | Positive | Positive | Positive | Positive | Positive | Positive | TNS1-ALK | 0 | 0 | 0 |
| 3 | Negative | Positive | Positive | Negative | Positive | Positive | LBH-ALK | 1 | Gemcitabine/Docetaxel | 0 |
| 4 | Positive | Not performed | Not performed | Not performed | Positive | Not performed | IGFBP5 -ALK | 3 | Doxorubicin/olaratumab Gemcitabine/docetaxel Pazopanib |
0 |